UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1416-2
Program Prior Authorization/Notification
Medication Vowst™ (fecal microbiota spores, live-brpk)
P&T Approval Date 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Vowst is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in
individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).
2. Coverage Criteriaa:
A. Authorization
1. Vowst will be approved based on all of the following criteria:
a. Diagnosis of recurrent Clostridioides difficile infection (rCDI)
-AND-
b. Patient is 18 years of age or older
-AND-
c. Patient has completed antibiotic treatment for rCDI 2 to 4 days prior to initiating
Vowst
-AND-
d. Vowst is used to prevent the recurrence of CDI
Authorization will be issued for 1 month
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place
• Prior Authorization/Medical Necessity may be in place
© 2024 UnitedHealthcare Services, Inc.
1
4. References:
1. Vowst [package insert]. Cambridge, MA: Seres Therapeutics, Inc.; April 2023.
Program Prior Authorization/Notification - Vowst™ (fecal microbiota spores,
live-brpk)
Change Control
7/2023 New program.
7/2024 Annual review with no changes.
© 2024 UnitedHealthcare Services, Inc.
2